"FDA Approves Leqembi, a Breakthrough Alzheimer's Drug to Slow Disease Progression"

The U.S. Food and Drug Administration (FDA) has granted full approval to the Alzheimer's drug Leqembi (lecanemab), making it the first medication to slow the progression of the disease by targeting its underlying biology. Developed by Eisai and Biogen, Leqembi has shown clinical benefit in slowing declines in memory and thinking. The FDA's decision was based on a larger study involving 1,800 patients, which showed a small but significant improvement in cognitive function. However, the drug is not a cure and comes with downsides such as the need for regular infusions and possible side effects. Access to the drug may also be an issue due to its expected high cost.